IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile.
Cell Mol Life Sci. 2022 Mar 5;79(3):177. doi: 10.1007/s00018-022-04207-3.
There is a steadily growing interest in the use of mitochondria as therapeutic agents. The use of mitochondria derived from mesenchymal stem/stromal cells (MSCs) for therapeutic purposes represents an innovative approach to treat many diseases (immune deregulation, inflammation-related disorders, wound healing, ischemic events, and aging) with an increasing amount of promising evidence, ranging from preclinical to clinical research. Furthermore, the eventual reversal, induced by the intercellular mitochondrial transfer, of the metabolic and pro-inflammatory profile, opens new avenues to the understanding of diseases' etiology, their relation to both systemic and local risk factors, and also leads to new therapeutic tools for the control of inflammatory and degenerative diseases. To this end, we illustrate in this review, the triggers and mechanisms behind the transfer of mitochondria employed by MSCs and the underlying benefits as well as the possible adverse effects of MSCs mitochondrial exchange. We relay the rationale and opportunities for the use of these organelles in the clinic as cell-based product.
人们对线粒体作为治疗剂的应用越来越感兴趣。利用间充质干细胞（MSCs）衍生的线粒体来治疗多种疾病（免疫失调、炎症相关疾病、伤口愈合、缺血事件和衰老）是一种创新的方法，越来越多的有前景的证据，从临床前研究到临床研究都有涉及。此外，细胞间线粒体转移诱导的代谢和促炎表型的逆转，为理解疾病的病因、它们与全身和局部危险因素的关系开辟了新的途径，并为控制炎症和退行性疾病提供了新的治疗手段。为此，我们在这篇综述中阐述了 MSC 中线粒体转移所涉及的触发因素和机制，以及 MSC 线粒体交换的潜在益处和可能的不良反应。我们还阐述了将这些细胞器作为细胞产品在临床上应用的原理和机会。
